The mission of Evans Life Sciences is to prevent the cycle of exporting raw medicinal plants (Bio-mass) by pioneering their processing into high-value intermediates and final Active Pharmaceutical Ingridients (API) within Nepal. We are dedicated to creating a new, value-added export paradigm for our country, with a vision to become the world's most trusted source for Himalayan plant-based ingredients, fueling both global health innovation and sustainable national economic growth.
Our Mission
Our
Story
Get to Know Us
Founded in 1996, Evans Life Sciences Pvt. Ltd. is a pioneer in the extraction and purification of Taxus derived anti-cancer medicines and natural compounds from medicinal plants, flowers, and barks. The company has developed Key starting material 10 DAB III used for purification of Paclitaxel and Docetaxel, a very potent ant- cancer drugs, beside expertise in processing botanicals with high therapeutic value and aims to position itself as Nepal’s first herbal-based Active Pharmaceutical Ingredients (API) ie Pharmaceutical and ayurvedic raw material manufacturer.
Strategic Revival and Ownership
After facing operational challenges due to a government-imposed export ban on Taxus products under the CITES Act and internal disruptions, Evans Life Sciences has been successfully revived under new ownership. The company is now managed by TIME Pharmaceuticals Pvt. Ltd., with major investments from TIME Pharma Investment Pvt. Ltd. and NPI Narayani Samudayik Hospital Ltd., Bharatpur. This revival marks a new phase of strategic growth, modernization, and operational excellence.
Core Expertise and Product Line
Evans specializes in producing key intermediates for anti-cancer APIs, including 10Deacetyl Baccatin III (10-DAB-III), 7-Troc Paclitaxel, and 7,10-Di-Troc Docetaxel, derived from the Taxus species (Lauthsalla or Himalayan Yew). With rising global demand— estimated to reach USD 5 billion in the next five years—Evans is ideally positioned to capture a growing share of this high-value global anti-cancer market. The company sources raw materials sustainably from government and private forests, as well as through commercial cultivation by mid-hill farmers, generating rural livelihood opportunities and promoting remote economical benefits alongside ecological conservation.
Production Capacity and Research Initiatives
Having obtained all necessary DDA approvals, Evans has tripled its production capacity and now manufactures 10-DAB-III, 7-Troc Paclitaxel, and Berberine HCl, with expansion plans to introduce Curcumin, Reetha, and Escin from FY 2081/82. Additional R&D efforts are ongoing for Chiraita Extract, Podophyllotoxin, Artemisinin, Ginger extracts, and many rare herbal medicinal derivatives and many essential oils. The company’s associate company, Zydin Biotech Pvt. Ltd., is developing a state-of-the-art facility in Chitwan to produce anti-cancer APIs such as Paclitaxel, Docetaxel, Vincristine, and podophylin, meeting EU and US FDA accreditation standards. Zydin Biotech will primarlily utilize Evans’ intermediates as core raw materials; creating a vertically integrated pharmaceutical ecosystem within Nepal.
Our
Vision
Our Vision
To be recognized as a global leader in the production of high-value phytochemicals and pharmaceutical intermediates, driving innovation in healthcare while positioning Nepal as a premier hub for sustainable and ethical life sciences manufacturing.
Our Short-term Objectives
-
Enhance production capacity and efficiency for key phytochemicals like 10-DAB III and essential oils.
-
Ensure strict adherence to quality standards and regulatory compliance for APIs and natural extracts.
-
To obtain GMP certification from Nepal Govt DDA.
-
Expand domestic market presence in Nepal for nutraceutical and personal care products.
-
Develop strategic partnerships with research institutions and pharmaceutical companies.
-
Strengthen sustainable sourcing practices for raw materials like Taxus Wallichiana and Chiraita, berberis.
-
To start company’s own cultivation and promote contract cultivation of few rare herbal medicines.
Our Long-term Objectives
-
To Establish Evans Life Sciences as a leading global supplier of high-value APIs and phytochemicals.
-
Expand international market reach for oncology, cardiology, and nutraceutical products.
-
Invest in R&D for novel drug intermediates and natural compounds.
-
Promote Nepal as a trusted hub for ethical, high-quality herbal and life sciences manufacturing.
-
Foster sustainable and innovative practices to ensure long-term rural economy, environmental and social responsibility.
Our Impact
Our Impact
1
Economic Growth
Driving Nepal’s pharmaceutical growth by meeting global demand for high-value oncology APIs and strengthening the national industrial base.
2
Job Creation
Creating high-skilled jobs in R&D and manufacturing, while supporting thousands of livelihoods through local agricultural and logistics partnerships.
3
Social Impact
Improving living standards in mid-hill regions by providing sustainable income through the commercial cultivation of Taxus and Himalayan herbs.
4
Import Substitution
Reducing dependency on pharmaceutical imports by producing world-class Active Pharmaceutical Ingredients (APIs) right here in Nepal.
5
Exports
Boosting foreign exchange and improving trade balance as a premier exporter of oncology intermediates to major markets like India and China.
6
Environmental Sustainability
Promoting reforestation and biodiversity by cultivating herbal species on private and managed forest lands across the Himalayas.
7
Healthcare Improvement
Improving patient outcomes by ensuring the domestic availability of essential anti-cancer medications and life-saving therapies.